Share Price of This Pharma Company Zooms 11.5% Intraday Despite Poor Q4 Figures; Here’s Why

Shares of Balaxi Pharmaceuticals Ltd surged on June 2nd, despite the company posting lackluster financial results for the period ending March 31, 2025. The small-cap stock, which trades below Rs 100, defied the earnings headwinds and sparked a relative rally with shares shooting up 11.5% in intraday trading, ultimately peaking at Rs 57.24 on the NSE.

The firm reported a net loss of Rs 117.85 lakh for the 4th fiscal quarter of 2025, which is a significant increase from the net loss of Rs 57.52 lakh registered during the previous year's quarter. Additionally, the company's total income for Q4FY25 also reportedly plunged drastically by 37.9% year-on-year to Rs 996.98 lakh, down from Rs 1,606.86 lakh in Q4 FY24.

Performance, on the other hand, was also worse relative to the last fiscal quarter. Revenue also dropped lower than the last quarter at Rs 1,407.49 lakh in Q3 FY25, which was a dip of 29%. Furthermore, the firm turned to a loss from their previous net profit of Rs 174.32 lakh in the prior quarter. The firm cited their revenue performance coupled with consistently high input and operational costs as reasons for the significant decline.

Even with the quarterly loss, Balaxi Pharmaceuticals' sustained remains positive on a yearly basis. The company's net profit stood at Rs 360.13 lakh for FY25, which is less than Balaxi's FY24 profit of Rs 365.04 lakh. The company's revenue from operations also declined in FY 25, standing at Rs 6,098.82 lakh, which shows a 5.6% decline from the previous fiscal year's revenue of Rs 7,019.60 lakh.

The investor sentiment in this stock did seem to change this year after the bulk transactions executed on March 3. Ebisu Global Opportunities Fund Limited purchased 45 lakh shares at Rs 53 per share; this brought their total stake in the company to 8.19%. In the same stroke, Unico Global Opportunities Fund Limited also bought 45.77 lakh shares at the same price, bringing their stake to 8.3%. Those sales were by MGC Fund Limited and Elala India Opportunities Fund, which sold the same amount of stock. The investments gave the stock some boost as well as contributed to its rally.

Balaxi Pharmaceuticals operates in the branded formulations sector and, along with several therapeutic areas, gives the company greater market access for African, Latin American, and Caribbean nations, giving it an edge in terms of distribution and IP products. The company's global reach extends to these regions due to its strong distribution network and focus on IP protected goods.

The company does face some short-term headwinds. However, the renewed interest from strategic investors and its position in international markets can help the company navigate through its struggles.